江苏康缘药业股份有限公司 关于公司控股股东因公司回购注销限制性股票 持股比例被动增加触及1%整数倍的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券简称：康缘药业 证券代码：600557 公告编号：2025-023 本次回购注销完成后，公司控股股东江苏康缘集团有限责任公司（以下 简称"康缘集团"）在持有公司的股份数量不变的情况下，持有公司股份比例 由 30.94%被动增加至 31.12%，适用权益变动触及 1%整数倍的情形。本次权益 变动不会导致公司控股股东及实际控制人发生变化。 江苏康缘药业股份有限公司已于 2025 年 5 月 29 日办理完成回购注销公司 2022 年度限制性股票激励计划剩余全部限制性股票事宜。本次回购注销导致公 司控股股东江苏康缘集团有限责任公司在持有公司的股份数量不变的情况下， 持有公司股份比例由 30.94%被动增加至 31.12%，适用权益变动触及 1%整数倍 的情形，具体情况如下。 一、本次限制性股票回购注销完成情况 公司本次回购注销的限制性股票数量为 330,03 万股，本次回 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-022 一、审议通过《关于变更法定代表人的议案》 公司董事会拟将法定代表人由董事长肖伟先生变更为代表公司执行公司事务的 董事高海鑫先生，该变更符合《中华人民共和国公司法》《上海证券交易所上市公 司自律监管指引》等法律法规以及康缘药业《公司章程》第八条的相关规定。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 董事会授权相关人员依规办理工商登记变更事宜，具体以工商行政管理部门登 记为准。 江苏康缘药业股份有限公司 第八届董事会第十九次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司""康缘药业"）第八届董事会 第十九次临时会议通知于 2025 年 5 月 28 日以书面文件、电话和电子邮件方式发出， 会议于 2025 年 5 月 30 日在公司会议室以现场结合通讯方式召开。应出席会议董事 9 人，实际出席会议董事 9 人。本次会议的召开符合《公司法》等法律法规以及《公 司章程》的规定。会议由董事长肖伟 ...

Group 1 - Kangyuan Pharmaceutical has launched a significant generic drug, Sumatriptan Naproxen Sodium Tablets, which fills a gap in the domestic market as the original manufacturer has not yet received approval for entry [2] - The sales of neurological system drugs in China remain substantial, maintaining a scale of over 100 billion yuan, with analgesics holding a market share exceeding 17% [2] - This new drug is the third product approved for Kangyuan Pharmaceutical this year, alongside other products in the neurological field, including Piracetam Injection and Pirfenidone Tablets [2] Group 2 - Kangyuan Pharmaceutical is advancing its "one body, two wings" strategy, focusing on both traditional Chinese medicine and expanding into chemical and biological drugs [2][3] - The company has made significant progress in chemical drug development, particularly in antiviral and anti-tumor areas, enhancing its product matrix [2] - In 2024, Kangyuan Pharmaceutical will complete the acquisition of 100% of Zhongxin Pharmaceutical, which specializes in the development of recombinant human cytokines and antibody biological drugs, further solidifying its growth strategy [3]

Core Insights - In 2024, the company expects a decline in both revenue and net profit, with projected figures of 3.898 billion and 392 million respectively, representing year-on-year decreases of 19.86% and 15.58% [1] - The first quarter of 2024 continues to show pressure on performance, with revenue of 878 million, down 35.38% year-on-year, and net profit of 83.41 million, down 38.37% [1] - The decline in first-quarter revenue is primarily attributed to a decrease in sales of the core injection product, Heat Toxicity Ning Injection [1][2] Product Performance - The core injection products have historically driven high growth, with Heat Toxicity Ning Injection sales exceeding 1 billion in 2013, but experiencing significant fluctuations due to policy changes [2] - The 2023 National Medical Insurance Directory allowed for increased sales of Heat Toxicity Ning Injection, reaching 6.077 million units, but sales fell to 4.195 million units in 2024, with inventory levels increasing by 759.11% [2] - Ginkgo Biloba Diterpene Amine Injection has also contributed to revenue growth, but its price dropped significantly after negotiations, limiting its growth potential [3] - The company’s oral liquid product, Jin Zhen Oral Liquid, has shown inconsistent sales performance, with year-on-year changes of 74.81%, -22.67%, and 5.13% from 2022 to 2024 [3] Financial Overview - In the first quarter, the injection product category generated approximately 340 million in revenue, down 36.86% year-on-year [4] - The overall revenue for the company in the first quarter was 867.22 million, with a total revenue decline of 35.79% [7] - The company reported a significant decline in operating cash flow, down 59.9% to 77 million in the first quarter, raising concerns about balancing cash flow health with long-term investments [9] New Product Developments - The company has received approvals for several new traditional Chinese medicine products, but their contribution to overall revenue remains limited, with a 10.34% decline in revenue from granules and powders in 2024 [6] - The company has not disclosed sales figures for the "Scattering Cold and Dampness Granules," a product related to COVID-19 treatment, despite investor inquiries [8]

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has decided to repurchase and cancel a total of 3.3003 million restricted stocks from 155 incentive recipients due to unmet performance assessment criteria for the fiscal year 2024 [2][5][8] Group 1: Reasons for Repurchase and Cancellation - The repurchase and cancellation of restricted stocks are based on the failure to meet the performance assessment conditions outlined in the 2022 Restricted Stock Incentive Plan [4][5] - The specific conditions for lifting the restrictions included a revenue growth rate of no less than 18% or a net profit growth rate of no less than 20% for 2024, which were not achieved [4][5] - The company reported a revenue of 389.77 million yuan for 2024, a decrease of 19.86% year-on-year, and a net profit of 39.19 million yuan, down 15.58% year-on-year [5] Group 2: Details of the Repurchase and Cancellation - The decision to repurchase was approved in the board and supervisory meetings held on April 2, 2025, and the relevant announcements were disclosed on April 3, 2025 [3][4] - The repurchase will be executed through a dedicated securities account, with the cancellation expected to be completed by May 29, 2025 [6] - After the cancellation, the 2022 Restricted Stock Incentive Plan will be fully concluded [8] Group 3: Legal and Compliance Aspects - The company has ensured that the decision-making process and information disclosure comply with relevant laws and regulations, including the Management Measures for Equity Incentives [9][10] - A legal opinion has confirmed that the necessary authorizations and approvals for the repurchase and cancellation have been obtained [10]

证券简称：康缘药业 证券代码：600557 公告编号：2025-021 江苏康缘药业股份有限公司 关于公司2022年度限制性股票激励计划剩余 全部限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因 鉴于江苏康缘药业股份有限公司（以下简称"公司"）2024 年度公司层面考 核条件未达标，公司 2022 年度限制性股票激励计划首次授予及预留部分首批授 予第三个解除限售期、预留部分第二批授予第二个解除限售期解除限售条件未成 就，根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、公司 《2022 年度限制性股票激励计划（更正后）》（以下简称"《激励计划》"或 "本次激励计划"）的规定及 2021 年年度股东大会的授权，公司决定将上述涉 及的 155 名激励对象已获授但尚未解除限售的限制性股票共计 330.03 万股进行 回购注销。 本次注销股份的有关情况 | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | --- | --- | --- ...

回 购 注 销 剩 余 全 部 限 制 性 股 票 实 施 情 况 的 关 于 江 苏 康 缘 药 业 股 份 有 限 公 司 江 苏 世 纪 同 仁 律 师 事 务 所 2022 年 度 限 制 性 股 票 激 励 计 划 法 律 意 见 书 苏 同 律 证 字 2025 第 [101]号 南 京 市 建 邺 区 贤 坤 路 江 岛 智 立 方 C 座 4 层 邮 编 ： 2 1 0 0 1 9 电 话 ： + 8 6 2 5 - 8 3 3 0 4 4 8 0 传 真 ： + 8 6 2 5 - 8 3 3 2 9 3 3 5 江苏世纪同仁律师事务所 法律意见书 江苏世纪同仁律师事务所关于 江苏康缘药业股份有限公司 2022 年度限制性股票激励计划 回购注销剩余全部限制性股票实施情况的 法 律 意 见 书 苏同律证字（2025）第[101]号 致：江苏康缘药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》（以下简称"《证券法》"）《上海证券交易所股票上市规则》（以 下简称"上市规则"）《上市公司股权激励管理办法》（以下简称"《管理办法》"） 等有关法律、法规 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-020 江苏康缘药业股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 会议召开时间：2025 年 5 月 29 日（星期四）13:30-14:30 ? 会议召开地点：上证路演中心 http://roadshow.sseinfo.com ? 会议召开方式：上证路演中心网络互动 ? 投资者可于 5 月 27 日(星期二)16:00 前登录上证路演中心网站首页点击"提 问预征集"栏目进行提问，公司将在说明会上对投资者普遍关注的问题进行解答。 江苏康缘药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 3 日、 及上海证券交易所网站www.sse.com.cn披露了公司《2024 年年度报告》《2025 年第一季度报告》。为便于广大投资者更全面深入地了解公司 2024 年及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 5 月 29 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-020 江苏康缘药业股份有限公司 关于召开 2024 年度暨 2025 年第一季度 一、说明会类型 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 5 月 27 日(星期二)16:00 前登录上证路演中心网站首页点击"提 问预征集"栏目进行提问，公司将在说明会上对投资者普遍关注的问题进行解答。 江苏康缘药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 3 日、 2025 年 4 月 30 日在《上海证券报》《中国证券报》《证券日报》《证券时报》 及上海证券交易所网站www.sse.com.cn披露了公司《2024 年年度报告》《2025 年第一季度报告》。为便于广大投资者更全面深入地了解公司 2024 年及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 5 月 29 日（星期四） 13:30-14:30 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资者关心的问 ...

Core Insights - The "Su Xin Consumption · Summer Night Life" event held from May 15 to 18, 2025, in Lianyungang showcased a blend of global products and traditional culture, highlighting the vitality of traditional health culture in modern consumption scenarios [1][2]. Group 1: Event Overview - The event attracted over 200 foreign trade enterprises and local brands from 13 cities in the province, focusing on integrated domestic and foreign trade and online shopping [2]. - The exhibition featured a variety of products, including health products from Kangyuan Group's Anxilai brand, which emphasizes the fusion of Eastern dietary concepts with foreign trade goods [2]. Group 2: Targeting Young Consumers - Anxilai has identified the trend of traditional health practices appealing to younger consumers, leveraging the company's strong research and development capabilities to create products that meet modern nutritional standards [3]. - The brand's products, such as ready-to-eat snacks and drinks, have gained popularity among young consumers due to their convenience and clean ingredients [3]. Group 3: Technological Innovations and Services - Anxilai focuses on innovation and user needs, creating an integrated online and offline consumption ecosystem [4]. - The brand offers personalized health management services through its mini-program, allowing consumers to receive tailored dietary recommendations based on AI analysis [4]. - Anxilai aims to contribute to the inheritance and innovation of traditional Chinese culture while meeting consumer health needs through expert education and personalized services [4].